跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AB-14
首页
药物
AB-14
AB-14
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
US 10415015 B2
申请人: IOVANCE BIOTHERAPEUTICS INC
优先权: 2017
US
4 件公开
MACROCYCLIC PEPTIDE COMPOUND HAVING CELL MEMBRANE PERMEABILITY AND METABOLIC STABILITY, AND LIBRARY CONTAINING SAME
EP 4768499 A1
申请人: CHUGAI PHARMACEUTICAL CO LTD
优先权: 2023
CN
EP
WO
3 件公开
Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US 2006057231 A1
申请人: RIMANDO AGNES M
优先权: 2004
US
WO
2 件公开
Novel strain of sars-associated coronavirus and applications thereof
EP 2275534 A1
申请人: PASTEUR INSTITUT
优先权: 2004
EP
2 件公开
Medicinal salt of fused ring compound, crystal form and application thereof
CN 119684314 A
申请人: SUZHOU SHENGDIYA BIOLOGICAL MEDICINE CO LTD
优先权: 2024
CN
2 件公开
一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
CN 119684315 B
申请人: 苏州盛迪亚生物医药有限公司
优先权: 2024
CN
2 件公开
一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
CN 119490512 B
申请人: 苏州盛迪亚生物医药有限公司
优先权: 2024
CN
2 件公开
Agonist antibodies that bind to the TWEAK receptor Fn14, thereby modulating adiposity-associated phenotypes, and their use in therapy
EP 1764109 A1
申请人: XANTOS BIOMEDICINE AG
优先权: 2005
EP
Alkyl benzoate mixtures
EP 1905483 A1
申请人: COGNIS IP MAN GMBH
优先权: 2006
EP
Anti-idiotypic antibodies neutralising the inhibiting activity of an inhibiting antibody directed against domain C1 of factor VIII
EP 2447284 A1
申请人: LFB BIOTECHNOLOGIES
优先权: 2007
EP
第 1 / 3 页
上一页
下一页
药物
反馈